These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1519 related articles for article (PubMed ID: 25538310)

  • 1. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
    Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR
    Diabetes Care; 2015 Jan; 38(1):140-9. PubMed ID: 25538310
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149.
    McCormack JP; Martin SA; Newman DH
    Diabetes Care; 2015 Sep; 38(9):e141-2. PubMed ID: 26294778
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149.
    Landman GW; Kleefstra N; Houweling ST
    Diabetes Care; 2015 Aug; 38(8):e127. PubMed ID: 26207067
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149.
    Mazzucchelli C; Bordone C; Maggi D; Cordera R
    Diabetes Care; 2015 Aug; 38(8):e125-6. PubMed ID: 26207066
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149.
    Herman WH
    Diabetes Care; 2015 Sep; 38(9):e143. PubMed ID: 26294779
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149.
    Inzucchi SE; Matthews DR;
    Diabetes Care; 2015 Aug; 38(8):e128-9. PubMed ID: 26207068
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
    Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR
    Diabetologia; 2015 Mar; 58(3):429-42. PubMed ID: 25583541
    [No Abstract]   [Full Text] [Related]  

  • 12. Response letter to D. Singh-franco et al.
    Owens DR; Del Prato S; Taskinen MR; Gomis R; Forst T; Woerle HJ
    Diabetes Obes Metab; 2012 Nov; 14(11):1054-5. PubMed ID: 23034010
    [No Abstract]   [Full Text] [Related]  

  • 13. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR
    Diabetologia; 2012 Jun; 55(6):1577-96. PubMed ID: 22526604
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
    Tanaka K; Ogawa Y; Shimada S
    J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Pratley RE
    Expert Opin Pharmacother; 2009 Feb; 10(3):503-12. PubMed ID: 19191685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.